AMN
Amn Healthcare Services IncPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EBITDA non-GAAP | $166M | Q1 2026 call | — |
| adjusted EBITDA margin non-GAAP | 12.1% | Q1 2026 call | — |
| AI recruiter clinicians deployed | 10,000 | Q1 2026 call | — |
| leverage ratio | 1.6 | Q1 2026 call | — |
| Passport monthly active users year-over-year growth | 50% | past year call | — |
| Passport users year-over-year growth | 30% | past year call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMN
this stock
Amn Healthcare Services Inc
|
$1.33B | +105.3% | +4.5% | — | 8.4% |
|
HCA
HCA Healthcare, Inc.
|
$85.57B | -18.7% | +7.1% | 13.3 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.10B | -16.2% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.09B | -3.2% | -2.3% | 10.3 | 4.3% |
|
DVA
Davita Inc.
|
$15.02B | +103.9% | +6.5% | 21.9 | 7.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMN | +0.8% | +4.8% | +67.6% | -0.1% | +105.3% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -0.4% | +4.9% | +57.5% | -1.1% | +94.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.